|
Co-Development & Target In-Licensing
Overview |
Funded R&D |
Library Licensing |
Patent Licensing |
In-Licensing
One of Dyax's key priorities is the continual expansion of our pipeline of biopharmaceutical product candidates. Our current pipeline focuses on targets in oncology and inflammation.
Work with Us...
If your company or academic institution has identified targets for which an antibody or protein therapeutic is desirable, we'd like to talk to you. Targets of specific interest to Dyax include:
- Receptors at the cell surface for cytokines, paracrine factors, and hormones
- Enzymes located at the cell surface or secreted into the extracellular space or circulation
- Antigens with clearly increased expression on tumor cells and limited distribution elsewhere
- Circulating factors
- Adhesion molecules expressed on lymphocytes upon immune system activation
...and We'll Work with You.
Dyax is very flexible in the types of business arrangements we utilize to gain access to novel therapeutic targets.
- Dyax has signed several co-development agreements in which we utilize our antibody and protein libraries to discover therapeutic products to our partner's novel target. Under this type of agreement, the two parties equally share development costs and any product revenues.
- Dyax has signed several in-licensing agreements in which Dyax obtains the intellectual property rights to novel targets. Dyax is solely responsible for the identification, development, and commercialization of the antibody or protein therapeutics to the target. License fees, maintenance fees, milestones, and royalties are paid to the academic institution or company that licensed its intellectual property to Dyax.
Contact our Business Development team:
|
